New 'Pro Version' of Cisplatin Shows Promise in Reducing Side Effects for Cancer Patients
Researchers have developed a new molecule, cisproplatin, which combines cisplatin and probenecid to treat cancer while minimizing harmful side effects. Cisplatin is a widely used cancer drug known for its effectiveness but also for causing significant damage to healthy organs, particularly the kidneys and peripheral nerves. The new compound, cisproplatin, is designed to remain stable in the body and activate only in tumor-like conditions, thereby reducing the risk of damage to healthy tissues. Initial tests have shown that cisproplatin is effective against a variety of cancer cell lines, including breast, melanoma, and lung cancers, often outperforming standard cisplatin. The research, published in the Journal of Medicinal Chemistry, indicates that cisproplatin could potentially offer a more targeted cancer treatment with fewer side effects. 
